Published in Antimicrob Agents Chemother on September 01, 2003
Large porous particles for pulmonary drug delivery. Science (1997) 3.35
Fluorometric determination of isonicotinic acid hydrazide in serum. J Lab Clin Med (1967) 1.50
Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother (1989) 1.16
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother (2001) 1.01
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents (2001) 0.97
Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids. Indian J Med Res (1980) 0.97
Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother (2001) 0.95
Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer. Tuber Lung Dis (1994) 0.95
Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res (2001) 0.90
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (2001) 0.82
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother (2003) 1.49
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) (2005) 1.25
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) (2003) 1.18
Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J (2000) 1.15
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents (2005) 1.14
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett (2005) 1.13
Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother (2005) 1.11
Phospholipids of Clostridium butyricum. V. Effects of growth temperature on fatty acid, alk-1-enyl ether group, and phospholipid composition. J Lipid Res (1974) 1.09
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett (2006) 1.09
The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett (2006) 1.05
Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm (2005) 1.04
Pulmonary epithelial cells are a source of interferon-gamma in response to Mycobacterium tuberculosis infection. Immunol Cell Biol (2007) 1.03
Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents (2006) 1.02
Signaling through protein kinases and transcriptional regulators in Candida albicans. Crit Rev Microbiol (2003) 1.02
Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother (2001) 1.01
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother (2001) 1.01
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother (2004) 0.99
Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm (2002) 0.99
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents (2001) 0.97
Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to Mycobacterium tuberculosis. Immunology (2004) 0.97
Role of interleukin-6 as an early marker of fat embolism syndrome: a clinical study. Clin Orthop Relat Res (2013) 0.96
Further studies on the lipids of corynebacteria. The mannolipids of Corynebacterium aquaticum. Biochem J (1972) 0.96
Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol (2007) 0.95
Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents (2004) 0.94
A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect (2006) 0.94
Effects of growth temperature and supplementation with exogenous fatty acids on some physical properties of Clostridium butyricum phospholipids. Biochim Biophys Acta (1977) 0.94
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (1997) 0.94
Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis (2004) 0.93
Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) (2005) 0.92
Biochemical interaction of human neutrophil peptide-1 with Mycobacterium tuberculosis H37Ra. Arch Microbiol (1999) 0.92
Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 0.92
On the mannophosphoinositides of Mycobacterium 607. Experientia (1968) 0.92
Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother (2006) 0.92
Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int J Antimicrob Agents (2007) 0.91
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother (2003) 0.91
Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother (2004) 0.91
Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif (2006) 0.90
Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci (2008) 0.90
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother (2004) 0.90
Liposome technology for drug delivery against mycobacterial infections. Curr Pharm Des (2004) 0.90
Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect Immun (2005) 0.90
Comparative evaluation of the diagnostic significance of circulating immune complexes and antibodies to phosphatidylinositomannosides in pulmonary tuberculosis by enzyme-linked immunosorbent assay. Med Microbiol Immunol (1989) 0.90
Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. Eur Respir J (2006) 0.89
DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol Cell Biol (2001) 0.88
Immunoprophylactic properties of 71-kDa cell wall-associated protein antigen of Mycobacterium tuberculosis H37Ra. Med Microbiol Immunol (1997) 0.88
Effect of acute administration of dichlorodiphenyl trichloroethane on certain enzymes of Rhesus monkey. Indian J Med Res (1978) 0.88
Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine (2005) 0.88
Cell wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother (1990) 0.88
Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv (2004) 0.87
Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine (2007) 0.87
Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine (2005) 0.87
Immunogenicity of ribonucleic acid-protein fraction of Mycobacterium tuberculosis encapsulated in liposomes. J Med Microbiol (1989) 0.87
Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin Immunol (2007) 0.86
Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study. Int J Antimicrob Agents (2001) 0.86
Liposomes as a carrier for mannophosphoinositide antigens of mycobacteria. Indian J Biochem Biophys (1993) 0.86
Lipid metabolism in fungi. Crit Rev Microbiol (1984) 0.86
Replacement of acyl and alk-1-enyl groups in Clostridium butyricum phospholipids by exogenous fatty acids. Biochemistry (1975) 0.86
Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Drug Deliv (2010) 0.86
Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta (1997) 0.85
Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect (2006) 0.85
Changes in parathyroid proteome in patients with primary hyperparathyroidism due to sporadic parathyroid adenomas. Clin Endocrinol (Oxf) (2014) 0.84
Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci (2012) 0.84
Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents (2006) 0.84
Alginate-based sustained release drug delivery systems for tuberculosis. Expert Opin Drug Deliv (2008) 0.84
Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery. Expert Opin Ther Targets (2009) 0.83
Lipid composition and virulence of Mycobacterium tuberculosis H37Rv. Aust J Exp Biol Med Sci (1982) 0.83
Effect of growth temperature on the lipid composition of Mycobacterium smegmatis ATCC 607. J Gen Microbiol (1979) 0.83
Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J (2005) 0.83
Antigenicity of phosphatidyl inositomannosides of Mycobacterium tuberculosis. Immunochemistry (1971) 0.83
Alterations in macromolecular composition and cell wall integrity by ciprofloxacin in Mycobacterium smegmatis. Lett Appl Microbiol (1999) 0.83
Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents (2004) 0.82
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (2001) 0.82
Phenotypic interaction of simultaneously administered isoniazid and phenytoin in patients with tuberculous meningitis or tuberculoma having seizures. Eur J Pharmacol (2013) 0.81
Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol (1998) 0.81
Role of cyclic adenosine monophosphate in phospholipid synthesis in Mycobacterium smegmatis ATCC 607. Lipids (1995) 0.81
Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunol Med Microbiol (1994) 0.81
Ca2+/calmodulin dependent protein kinase from Mycobacterium smegmatis ATCC 607. Mol Cell Biochem (1998) 0.81
Cytotoxic and antimicrobial activities of endophytic fungi isolated from Bacopa monnieri (L.) Pennell (Scrophulariaceae). BMC Complement Altern Med (2014) 0.81
Acid phosphatase activity of promastigotes of Leishmania donovani: a marker of virulence. FEMS Microbiol Lett (1992) 0.80
Cloning, expression and N-terminal formylation of ESAT-6 of Mycobacterium tuberculosis H37Rv. Protein Expr Purif (2013) 0.80
Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur J Endocrinol (2013) 0.80
Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria. Med Microbiol Immunol (1988) 0.80
Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents. Indian J Biochem Biophys (1989) 0.80
On the ornithinyl ester of phosphatidylglycerol of Mycobacterium 607. J Bacteriol (1970) 0.80